Osteosarcoma is a bone tumor with a high incidence in children and adolescents. Chemotherapy for osteosarcoma is limited, and effective targeted drugs are urgently needed to treat osteosarcoma. Exosomes as a natural nano drug delivery platform have been widely studied and proven to have good drug delivery performance. However, the low production of exosomes hinders its development as a carrier. Exosome mimetics (EMs) as an alternative product of exosomes solve the problem of low production of exosomes and maintain the good performance of exosomes as carriers. In this study, bone marrow mesenchymal stem cells (BMSCs) were sequentially extruded to generate EMs to encapsulate doxorubicin (EM-Dox) to treat osteosarcoma. The results showed that we successfully prepared EMs of BMSC, and EM-Dox was prepared using an active-loading approach. Our engineered EM-Dox demonstrated significantly more potent tumor inhibition activity and fewer side effects than free doxorubicin. This novel biological nanomedicine system provides a promising opportunity to develop novel precision medicine for osteosarcoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662035 | PMC |
| http://dx.doi.org/10.1080/10717544.2022.2141921 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hydrogel-integrated exosome mimetics derived from osteogenically induced mesenchymal stem cells in spheroid culture enhance bone regeneration.
Biomaterials
January 2025
Division of Oral and Systemic Health Sciences, School of Dentistry, University of California, Los Angeles, CA, 90095, USA; Department of Bioengineering, University of California, Los Angeles, CA, 90095, USA. Electronic address:
Exosomes derived from mesenchymal stem cells (MSCs) offer a promising alternative to traditional cell-based therapies for tissue repair by mitigating risks associated with the transplantation of living cells. However, insufficient osteogenic capacity of exosomes diminishes their potential in bone tissue regeneration. Here, we report novel osteogenically induced exosome mimetics (EMs) integrated into injectable hydrogel carriers for improved bone regeneration.
View Article and Find Full Text PDFPlatelet membrane decorated exosomes enhance targeting efficacy and therapeutic index to alleviate arterial restenosis.
Theranostics
January 2025
Department of Vascular Surgery, Zhongshan Hospital Fudan University, Shanghai, 200032, PR China.
Article Synopsis
- Postinterventional restenosis poses challenges in treating peripheral vascular disease, as current drugs hinder endothelial repair while preventing neointima hyperplasia.
- Stem cell-derived exosomes offer therapeutic benefits by delivering functional microRNAs but face limitations in targeting and tissue uptake in injured vessels.
- To improve efficacy, researchers created platelet-mimetic exosomes (PM-EXOs) that enhance targeting to vascular injuries and promote endothelial repair with minimal side effects, demonstrating significant potential in reducing neointima formation.
Amniotic fluid-derived stem cells: potential factories of natural and mimetic strategies for congenital malformations.
Stem Cell Res Ther
December 2024
Center for Precision Environmental Health, Baylor College of Medicine, One Baylor Plaza, Houston, TX, USA.
Article Synopsis
- Mesenchymal stem cells (MSCs) from gestational tissues are promising for treating congenital malformations but face challenges like invasiveness, prompting the exploration of less risky alternatives like naturally occurring exosomes (EXOs) and their mimics (MIMs) from amniotic fluid-derived MSCs (AF-MSCs).
- The study involved creating MIMs, comparing their properties to EXOs, and evaluating their safety and distribution in a mouse model predisposed to neural tube defects.
- Results indicated that MIMs and EXOs have similar characteristics, with MIMs yielding three times more product, and no adverse effects were found in pregnant mice, making MIMs a promising, minimally invasive therapeutic option.
Phosphatidylserine-incorporated exosome mimetics encapsulating CXCR3 antagonist alleviate osteoporosis.
Adv Funct Mater
September 2024
Division of Oral and Systemic Health Sciences, School of Dentistry, University of California, Los Angeles, CA 90095, USA.
Exosomes derived from mesenchymal stem cells are an active area of research due to their therapeutic potential in treating osteoporosis. To further harness their therapeutic performance in modulating bone resorption, we have equipped exosomes with osteoclast-targeting moieties on their surface as well as chemokine receptor antagonists blocking osteoclast recruitment. Phosphatidylserine (PS), a membrane lipid exerting immunosuppressive and phagocytic signals, was incorporated in the membrane of exosome mimetics (EMs) to achieve a marked affinity for osteoclast precursors and potential anti-resorptive effects.
View Article and Find Full Text PDFBiologics-based technologies for highly efficient and targeted RNA delivery.
Mol Ther
January 2025
Laboratory of Genetic Technologies, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, First Moscow State Medical University (Sechenov University), Moscow 119435, Russia; Division of Biotechnology, Sirius University of Science and Technology, Sochi 354340, Russia; Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow 119192, Russia. Electronic address:
The demand for RNA-based therapeutics is increasing globally. However, their use is hampered by the lack of safe and effective delivery vehicles. Here, we developed technologies for highly efficient delivery of RNA cargo into programmable extracellular vesicle-mimetic nanovesicles (EMNVs) by fabricating hybrid EMNV-liposomes (Hybs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!